Da palonosetron kan øge passagetiden i tyktarmen, skal patienter med en anamnese med obstipation eller tegn på subakut tarmobstruktion overvåges efter indgiften.
As palonosetron may increase large bowel transit time, patients with a history of constipation or signs of subacute intestinal obstruction should be monitored following administration.